Better Therapeutics- Tradeable Rights - March 2021 Long Term Debt

As of the most recent data (September 2023), MCADR shows a long-term debt of $7.7M. That compares with $12M in the prior-year period — down 33.8% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, MCADR's long-term debt is now $7.7M (was $12M) — a 33.8% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Better Therapeutics- Tradeable Rights - March 2021 is outperforming or lagging.

Tracking MCADR's long-term debt over time shows whether Better Therapeutics- Tradeable Rights - March 2021 is scaling, shrinking, or reshaping that part of the business. The current reading is $7.7M That compares with $12M in the prior-year period — down 33.8% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this long-term debt page, Stockcircle has Better Therapeutics- Tradeable Rights - March 2021's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect long-term debt (currently $7.7M) with ownership activity and broader fundamentals.